Prescription drug · ANDA
oxcarbazepine NDC 70771-1843
Oxcarbazepine 300 mg/1 · Tablet · Oral · Zydus Lifesciences Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70771-1843-0 | 70771184300 | 1000 TABLET in 1 BOTTLE (70771-1843-0)Marketed from Jul 10, 2025 | |
| 70771-1843-1 | 70771184301 | 100 TABLET in 1 BOTTLE (70771-1843-1)Marketed from Jul 10, 2025 | |
| 70771-1843-4 | 70771184304 | 10 BLISTER PACK in 1 CARTON (70771-1843-4) / 10 TABLET in 1 BLISTER PACKMarketed from Jul 10, 2025 | |
| 70771-1843-5 | 70771184305 | 500 TABLET in 1 BOTTLE (70771-1843-5)Marketed from Jul 10, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- oxcarbazepine
- Generic name (nonproprietary)
- oxcarbazepine
- Active ingredients
- Oxcarbazepine — 300 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Zydus Lifesciences Limited
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211747
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
- Identifiers
- Product ID 70771-1843_a783b6fe-6bb8-4684-a7a5-107288a969abSPL ID a783b6fe-6bb8-4684-a7a5-107288a969abSPL set ID e23d8a74-b47b-462a-b09c-90bdd58a032eRxCUI 312136, 312137, 312138UNII VZI5B1W380UPC 0370771184415, 0370771184217, 0370771184316
- Pharmacologic class
- Anti-epileptic Agent
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470771184300followed by a unit qualifier and the quantityPackage 70771-1843-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Oxcarbazepine is indicated for: Adults: -Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: -Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years -Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years ( 1 ) Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
Excerpt only. Read the full label for complete information.